Thomas Schall - ChemoCentryx Founder, Chairman, CEO and Pres

CCXIDelisted Stock  USD 51.99  0.00  0.00%   

Chairman

Dr. Thomas J. Schall, Ph.D., is the Chairman of the Board, President, Chief Executive Officer of ChemoCentryx, From 1993 to March 1997, Dr. Schall worked at the DNAX Research Institute, a division of ScheringPlough Corporationrationration, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schalls laboratories have been responsible for the discovery or codiscovery of almost onethird of all known chemokine receptors since 2012.
Age 58
Tenure 12 years
Professional MarksPh.D
Phone650 210-2910
Webwww.chemocentryx.com
Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University. We believe Dr. Schall is qualified to serve on our board of directors because of his extensive executive leadership experience, many years of service as one of our directors and our President and Chief Executive Officer and extensive scientific expertise and knowledge of the chemokine system.

ChemoCentryx Management Efficiency

The company has return on total asset (ROA) of (18.55) % which means that it has lost $18.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. ChemoCentryx's management efficiency ratios could be used to measure how well ChemoCentryx manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 73.2 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. ChemoCentryx has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ChemoCentryx until it has trouble settling it off, either with new capital or with free cash flow. So, ChemoCentryx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ChemoCentryx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ChemoCentryx to invest in growth at high rates of return. When we think about ChemoCentryx's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

CHAIRMAN Age

John ThorntonBarrick Gold Corp
70
Thomas ReddinAsbury Automotive Group
60
Gregory EbelSea
50
Graham ShuttleworthBarrick Gold Corp
55
Tadashi YanaiFast Retailing Co
74
Thomas DeLoachAsbury Automotive Group
73
Xiaodong LiSea
46
MA BAIoneer Ltd American
66
Forrest LiSea
N/A
Li XiaodongSea
42
Christopher ColemanBarrick Gold Corp
51
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc. ChemoCentryx operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 178 people. ChemoCentryx (CCXI) is traded on NASDAQ Exchange in USA and employs 178 people.

Management Performance

ChemoCentryx Leadership Team

Elected by the shareholders, the ChemoCentryx's board of directors comprises two types of representatives: ChemoCentryx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoCentryx. The board's role is to monitor ChemoCentryx's management team and ensure that shareholders' interests are well served. ChemoCentryx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoCentryx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Israel Charo, Senior Vice President - Research
Jan Hillson, Senior Vice President - Drug Development
Geoffrey Parker, Independent Director
Susan Kanaya, CFO, Sr. VP of Fin. and Secretary
Petrus Bekker, Senior Vice President - Clinical and Medical Affairs
Joseph Feczko, Independent Director
Markus Cappel, Chief Bus. Officer and Treasurer
William Fairey, COO, Executive Vice President
Thomas Edwards, Independent Director
James Tyree, Independent Director
Henry McKinnell, Director
Rajinder Singh, Senior Vice President - Research
Roger Lucas, Lead Independent Director
Rita Jain, Independent Director
Thomas Schall, Founder, Chairman, CEO and Pres

ChemoCentryx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoCentryx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with ChemoCentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoCentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoCentryx will appreciate offsetting losses from the drop in the long position's value.

Moving together with ChemoCentryx Stock

  0.81REGN Regeneron Pharmaceuticals Financial Report 2nd of May 2024 PairCorr

Moving against ChemoCentryx Stock

  0.66GFGY Granite Falls EnergyPairCorr
  0.58WXIBF WuXi BiologicsPairCorr
  0.56PRSEF ProsafePairCorr
  0.47FINN First NationalPairCorr
  0.44AMKBF AP Mller -PairCorr
The ability to find closely correlated positions to ChemoCentryx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoCentryx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoCentryx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoCentryx to buy it.
The correlation of ChemoCentryx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoCentryx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoCentryx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoCentryx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in ChemoCentryx Stock

If you are still planning to invest in ChemoCentryx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ChemoCentryx's history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets